1 / 1
Custom Deslorelin CAS 57773-65-6: Leading China Suppliers and Factory for Synthetic GnRH Analog Products Manufacturer, Pricelist
Product Description
Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) analog with a potency approximately 30–150 times that of natural GnRH. As a GnRH agonist, it initially and briefly stimulates the pituitary gland to release gonadotropins (the "flare-up" effect). Subsequently, through sustained agonistic action, it leads to pituitary desensitization and downregulation of GnRH receptors, thereby inhibiting the secretion of gonadotropins (LH, FSH) and ultimately suppressing the production of sex steroid hormones.
Therapeutic Areas
🐾 Veterinary application (approved)
- Animal reproductive management: Widely used for reproductive suppression or estrus cycle regulation in animals such as dogs, cats, and horses, such as suppressing estrus in female dogs and controlling sexual behavior in male horses.
- Treatment of animal diseases: Used to treat diseases related to sex hormones, such as prostate disease and hyperadrenocorticism in dogs.
🩺 Human medical applications (some are in the research/development stage)
- Reproductive endocrine disorders: It has been studied for the treatment of hormone-dependent diseases such as precocious puberty, endometriosis, and uterine fibroids.
- Prostate cancer and breast cancer: As a GnRH agonist, it can theoretically be used as adjuvant therapy for hormone-sensitive tumors, but other analogues (such as leuprorelin and goserelin) are more commonly used.
- Assisted reproductive technology: Pituitary downregulation in controlled ovarian stimulation (COS) cycles has been explored, but the current mainstream clinical drugs are other GnRH analogs.
Outlook & Development
- Veterinary application (approved)
- Animal reproductive management: Widely used for reproductive suppression or estrus cycle regulation in animals such as dogs, cats, and horses, such as suppressing estrus in female dogs and controlling sexual behavior in male horses.
- Treatment of animal diseases: Used to treat diseases related to sex hormones, such as prostate disease and hyperadrenocorticism in dogs.
- Human medical applications (some are in the research/development stage)
- Reproductive endocrine disorders: It has been studied for the treatment of hormone-dependent diseases such as precocious puberty, endometriosis, and uterine fibroids.
- Prostate cancer and breast cancer: As a GnRH agonist, it can theoretically be used as adjuvant therapy for hormone-sensitive tumors, but other analogues (such as leuprorelin and goserelin) are more commonly used.
- Assisted reproductive technology: Pituitary downregulation in controlled ovarian stimulation (COS) cycles has been explored, but the current mainstream clinical drugs are other GnRH analogs.
Conclusion
Deslorelin, as a GnRH agonist, is currently primarily valued in the veterinary field, particularly as a mature tool for companion animal reproductive control. In human medicine, its development has stalled due to market competition and patent issues. Future breakthroughs may depend on novel delivery systems or targeted therapy innovations, but it is unlikely to change the existing treatment landscape in the short term.
Frequently Asked Questions (FAQ)
What is Deslorelin?
Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) analog that is approximately 30–150 times more potent than natural GnRH.
How does Deslorelin work in the body?
It initially stimulates the pituitary gland to release gonadotropins, then causes desensitization and downregulation of GnRH receptors, ultimately suppressing the production of sex steroid hormones.
What are the main veterinary applications of Deslorelin?
It is widely used for animal reproductive management, such as suppressing estrus in dogs and cats, controlling sexual behavior in horses, and treating diseases like prostate disease and hyperadrenocorticism.
Is Deslorelin used in human medicine?
While primarily used in veterinary medicine, it has been studied for human reproductive endocrine disorders (like endometriosis), hormone-sensitive tumors, and assisted reproductive technology, though other analogs are more commonly used.
Why has Deslorelin's development in human medicine stalled?
Its development in human medicine has stalled primarily due to strong market competition from other established drugs and patent-related issues.
What is the future outlook for Deslorelin?
Future breakthroughs may depend on novel delivery systems or targeted therapy innovations, though it is unlikely to change the existing human treatment landscape in the short term.
